SPA
PYXS icon

Sherbrooke Park Advisers’s Pyxis Oncology PYXS Stock Holding History

Sherbrooke Park Advisers’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-18,890
Closed -$69.3K – 1088
2024
Q3 		$69.3K Buy
+18,890
New +$66.1K 0.02% 856

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Sherbrooke Park Advisers's PYXS Position: Q4 2024 in Review

Sherbrooke Park Advisers sold out of Pyxis Oncology (PYXS) in Q4 2024, closing a stake of 18,890 shares — an estimated $69.3K sold.

Sherbrooke Park Advisers first reported a position in PYXS in Q3 2024 and held it in 1 quarter. The position peaked at $69.3K in Q3 2024. 99 funds tracked by Wall St. Rank hold PYXS as of Q4 2024.

  • Sherbrooke Park Advisers reported no remaining Pyxis Oncology position as of Q4 2024 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 18,890 Pyxis Oncology shares in Q4 2024, an estimated $69.3K.
  • Sherbrooke Park Advisers first reported a position in Pyxis Oncology in Q3 2024 and held it in 1 quarter.
  • Sherbrooke Park Advisers's Pyxis Oncology position peaked at $69.3K in Q3 2024.
  • 99 funds tracked by Wall St. Rank held Pyxis Oncology as of Q4 2024.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.